Facts
as of Nov 20, 2026
BioCircuit Technologies is at the forefront of developing and commercializing advanced medical devices for tissue repair and neuromodulation. Our first commercial product, Nerve Tape®, is the first sutureless device for repairing transected nerves.
- Legal name
- BioCircuit Technologies, Inc.
- Headquarters
- Atlanta, United States
- Founded
- 2016
- Employees
- 51-200estimated range
- Register numbers
- EIN 812248893
These are the key facts about BioCircuit on Alion as of Nov 20, 2026. BioCircuit is headquartered in Atlanta, United States. It was founded in 2016. It has raised $13.7M in 3 funding rounds. The latest round is Convertible Note of $9M, announced in 2022.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Legal entity active
BioCircuit Technologies, Inc.
Not checked
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Named in the work visa registers of United States.
0H-1B filings in 12 months
0Open roles in United States
In the register as BioCircuit Technologies, Inc., Atlanta, GA
Other sponsors in the same field
Alert me
Footprint
Hiring in 1 city in 1 country.
Source: office addresses in postings and company registers
Financials
Funding rounds, investors and revenue on record.
$13.7MTotal raised
$10MPublic grants5 public grants
GrantLatest round
8Rounds and grants
Money by yearUSD, rounds and grants
2024$2.1M1 record
2023$6M3 records
2022$9M1 record
2021$3.2M1 record
2020$1.9M1 record
2019$1.5M1 record
Largest rounds and grants
Sources: funding announcements, grant and company registers
Money
BioCircuit has $13.7M paid in by investors, lenders and donors.
StagePaidSignedAnnouncedSourceFiledAnnouncedPress
Money in
Equity raised
Sep 2022 · Convertible note
$9MPaid
Equity raised
Apr 2021 · Convertible note
$3.2MPaid
Equity raised
May 2019 · Venture round
$1.5MPaid
Taxes
No public tax figures for this company or its entities.
People cost
BioCircuit filed a median H-1B wage of $313k in 2025.
$313kMedian H-1B wage, 20251 casesSource ↗
Median H-1B wage by role, 2025scale to $313k
Chief Operating Officer · 1$313k
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
1 public contract won, $350k in all. $350k of it in the last 12 months.
1Contracts
$350kValue
$350kIn 12 months
1Buyer countries
Biggest buyers
Defense Advanced Research Projects Agency
United States · 1 public contract
$350k
Latest awards
Defense Advanced Research Projects Agency, United States · 2026-01
$350k
Sources: USAspending federal contract awards - award notices naming the company's legal entities as the winner
Public record
BioCircuit in public registers.
Influence
Employees' political contributions, 2026 cycle
89 contributions · their own money, not the company's; names not shown ·
fec.gov ↗$4.4k
Each line links its register: the agency's page, the EU Transparency Register, the FEC, the USPTO, CourtListener.
Milestones
Each milestone is dated by its source: registers, filings, the press
Newsroom
Oct 282026
News · International Business Times
Axogen shares rose nearly 22% after the nerve repair company exceeded third-quarter earnings and revenue expectations, raised its 2026 sales forecast and reported progress on ins…
Oct 22026
News · Quiver Quantitative
Axogen acquires BioCircuit Technologies, enhancing its surgical solutions with NerveTape, a sutureless nerve repair device.Quiver AI SummaryAxogen, Inc. announced the completion…
Oct 12026
Press release · morningstar.com
Sources: the outlets named on each headline, each story once